X-Message-Number: 330
From att!CompuServe.COM!73337.2723 Mon May 13 09:04:08 EDT 1991
Date: 13 May 91 02:01:59 EDT
From: Brian Wowk <>
To: <>
Subject: can rattling
Message-Id: <"910513060158 73337.2723 DHJ26-1"@CompuServe.COM>

To: >INTERNET: 
 
        So Cryomedical Sciences has raised $13,000,000 from public investors,  
and Drs. Segall, Sternberg, and Waitz are ostensibly now millionaires after  
selling their stock.  Isn't that just great? 
 
        Perhaps Art Quaife could tell us exactly what CMS has PRODUCED (other  
than hype) to justify these kinds of rewards.  How much money from CUSTOMERS  
(as opposed to investors) has CMS brought in?  What kind of PROFIT has the  
company turned? 
 
        With regard to Trans Time, Art Quaife asks: 
 
        "Why would anyone give away $1000 to the can-rattler to further  
        cryonics, when he could invest the $1000 in a cryonics stock company,  
        achieve a comparable improvement in the state of the art, and next  
        year have his investment worth $1100?" 
 
        The notion that a dollar spent at Trans Time advances the "state of  
the art" as much as a dollar spent at Alcor is very interesting.  For years  
Alcor has led the way in ischemia research, freezing research, transport  
technology (with its ambulance, MALSS, and nationwide network of trained and  
equipped coordinators), suspension technology, physical security, and public  
education.  I can only infer from this that "can-rattler" Alcor must be  
rolling in cash, while for-profit Trans Time is in dire financial straits,  
investors notwithstanding. 
 
        Seriously.  Just what has Trans Time done for the "state of the art"  
in cryonics?  I still vividly recall the "state of the art" transport  
protocol employed by noted CMS researcher, Dr. P.S. on Trans Time patient,  
V.J. several years ago: Chest compressions without ventilation, setting a  
record for the lowest ph ever recorded in a cryonics patient. 
 
        The difference between Alcor and the aforementioned for-profit  
companies is simple.  Alcor has always been dedicated to tackling the  
practical and scientific problems of cryonics head-on.  The result has been,  
and continues to be, a physical capability far in advance of the other  
organizations.  At Alcor, we believe that for cryonics to succeed, people  
must want cryonics for THEMSELVES, not just to make a quick buck.  Our noted  
CMS researchers and associates, by contrast, have always demonstrated a  
penchant for grandstanding and hype artistry rather than science or physical  
capability.  In the May 9 posting from Art Quaife, you can actually see him  
boasting about how successful they've been, and will be, at raising money  
from investors (i.e. how good they are at generating hype). 
 
        Yet there is a very big difference between investors, and people who  
want cryonics for themselves.  Support from investors is a mile wide, but an  
inch deep.  The pyramid club can't go on forever, and sooner or later CMS  
will have to produce a major marketable product, and Trans Time will have to  
convince people they provide better cryonics services than the can-rattler  
competition.  Neither has happened yet. 
 
                                                --- Brian Wowk 

Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=330